In summary, we report the first case of an EML4-ALK+ lung adenocarcinoma patient with coexisting TP53, EGFR, and ERBB2 point mutations who achieved PR after three months of ensartinib treatment and reached SD at six months, which was maintained for approximately 30 months. Here, EGFR is linked to lung adenocarcinoma.